Datamonitor, June 2011, Pages: 94
Roche financial outlook
Key developments
[Missing title]
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Company
Datamonitor, Nov 2010, Pages: 104
: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
Chugai dominates the Japanese MAb landscape
SWOT analysis
Strengths
Weaknesses
Opportunities
Datamonitor, Oct 2009, Pages: 113
and competitors
Data sourcing
Sales data
Analyst consensus
Chapter 2 Executive summary
Key findings
Financial performance, 2002-14
Chugai: PharmaVitae forecasts at a glance
Strategic insight
The Roche
Datamonitor, May 2011, Pages: 95
purchase agreement with Sekisui Chemical
Phase III leukemia trial fails primary endpoint
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae
Datamonitor, June 2010, Pages: 116
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09
Operating costs and profit
Datamonitor, Nov 2008, Pages: 147
in this report 3
Figure 2: PharmaVitaes MDx classification scheme 4
Figure 3: The US vs. EU regulatory pathways 6
Figure 4: The IVD and MDx market size 2007 and 2013f 8
Figure 5: The key MDx tests 10
Figure 6
Datamonitor, Dec 2009, Pages: 114
-2014
Chapter 1 Introduction
Scope of analysis
Methodology
Company coverage
Data sources
Re-creating analysis from this report using PharmaVitae Explorer queries
Further reading
Chapter 2 Executive
Datamonitor, June 2008, Pages: 363
strategic analysis of the mAb market out to 2013
- Global sales forecasts to 2013 for marketed and Phase III mAb products
- Analysis of market trends by product, company, therapy area, technology and target
